Alkem Laboratories Limited — Others, 21-07-2025: Shareholders meeting

Alkem Laboratories has announced its 51st Annual General Meeting for shareholder approval of its annual financial results. The company reported consolidated revenue of ₹12,964.5 Cr, a 2.3% rise, with PAT up 20.6% to ₹2,165.5 Cr and EBITDA increasing 11.9% to ₹2,512.2 Cr. Domestic sales grew 6.5%, and non-US business saw 8.7% growth. The Board has approved a ₹8/share final dividend, bringing the total to ₹45/share. Strategic acquisitions of Adroit Biomed and Bombay Ortho, for ₹140 Cr and ₹147 Cr respectively, bolster its MedTech focus. Alkem maintains a strong ₹4,620 Cr net cash position.